Press releases

These press releases are intended for business journalists and analysts/investors

GSK reduces price for its first line treatment for chronic hepatitis B

GSK China today committed to reduce the price of its first-line chronic hepatitis B (CHB) treatment, patent-protected Viread® (tenofovir disoproxil fumarate)1, in China by up to 67%. This follows an announcement on the outcomes of a national price negotiation pilot by the National Health and Family Planning Commission (NHFPC) and other relevant government agencies.

Read more - GSK reduces price for its first line treatment for chronic hepatitis B Read more